Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bhalla

Showing results (151-160 of 189) with videos related to

Pageof 19
Sort By:
Nature Communications|December 13, 2022
Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseasesA Schäbitz, C Hillig, M Mubarak, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Leukemia|December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|March 12, 2026
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Blood Cancer Journal|May 21, 2025
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Pageof 19

Showing results (151-160 of 189) with videos related to

Sort By:
Pageof 19
Nature Communications|December 13, 2022
Spatial transcriptomics landscape of lesions from non-communicable inflammatory skin diseasesA Schäbitz, C Hillig, M Mubarak, et al.
Haematologica|December 9, 2016
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemiaJorge Cortes, Moshe Talpaz, Hedy P Smith, et al.
Leukemia|December 19, 2025
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Blood Cancer Journal|January 12, 2022
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)Warren Fiskus, Steffen Boettcher, Naval Daver, et al.
Blood|October 3, 2021
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2Christopher P Mill, Warren Fiskus, Courtney D DiNardo, et al.
Leukemia|March 12, 2026
Correction: BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AMLChristine E Birdwell, Warren Fiskus, Christopher P Mill, et al.
Leukemia|December 12, 2023
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpressionChristine E Birdwell, Warren Fiskus, Tapan M Kadia, et al.
Leukemia|March 3, 2021
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphomaWarren Fiskus, Christopher P Mill, Dimuthu Perera, et al.
Blood Cancer Journal|May 21, 2025
Correction: Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Blood Cancer Journal|April 13, 2023
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1Warren Fiskus, Christopher P Mill, Christine Birdwell, et al.
Pageof 19